Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samyr adjunctive therapy for major depressive disorder
2017-003073-33Phase 3Active
- Sponsor
- Mylan
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Samyr plus adjunctive antidepressant therapy with Placebo plus adjunctive antidepressant therapy (2 arms). Started Jul 2023; status: active.
02
Drugs
S-adenosylmethionine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-003073-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003073-33.